Factors associated with distant recurrence (DR) risk in patients (pts) with HR+/HER2-early breast cancer (EBC): a machine learning (ML) model-based analysis using real-world (RW) data

被引：0
|
作者：
Sparano, J. A. [1 ]
Lustberg, M. B. [2 ]
de Nonneville, A. [3 ]
Bachelot, T. [4 ]
Santa-Maria, C. A. [5 ]
Blyuss, O. [6 ]
Fasching, P. A. [7 ]
Brezden-Masley, C. [8 ]
Park, Y. H. [9 ]
Akdere, M. [10 ]
Ye, F. [11 ]
Pattipaka, T. [10 ,12 ]
Manneni, V. R.
Kurz, C. [13 ]
Castro, P. Dominguez [14 ]
Howard, F. M.
机构：
[1] Tisch Canc Inst, T Canc Inst, New York, NY 10029 USA
[2] Yale Univ, Sch Med, Sch Med, New Haven, CT USA
[3] Aix Marseille Univ, Inst Paoli Calmettes, CRCM, CNRS,INSERM,CRCM, Marseille, France
[4] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[5] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Breast & Gynecol Malignancies Grp, Baltimore, MD USA
[6] Queen Mary Univ London, Wolfson Inst Populat Hlth, Ctr Prevent Detect & Diag, London, England
[7] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen Comprehens Canc Ctr Erlangen EM, Erlangen, Germany
[8] Univ Toronto, Mt Sinai Hosp, Fac Med, Div Med Oncol & Hematol, Toronto, ON, Canada
[9] Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Div Hematol Oncol,Sch Med, Seoul, South Korea
[10] Novartis Pharm AG, Basel, Switzerland
[11] Novartis Pharmaceut, E Hanover, NJ USA
[12] Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India
[13] Novartis Pharma GmbH, Munich, Germany
[14] Novartis Ireland, Dublin, Ireland
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.104097
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P258
引用
收藏
页数：2
相关论文
共 36 条
  • [1] Prognostic variables for risk of recurrence in patients (pts) with HR+/HER2-early breast cancer (EBC) using data from the NATALEE trial: a machine learning (ML) model-based analysis
    Fasching, P. A.
    Barrios, C. H.
    Lim, E.
    Graff, S. L.
    Chia, S.
    Frenel, J. -s.
    Im, S. -a.
    Huang, C. -s.
    Ring, A.
    Nowecki, Z.
    Liu, Q.
    Akdere, M.
    Zarate, J. P.
    Hu, H.
    Pantoja, K.
    O'Shaughnessy, J. A.
    BREAST, 2025, 80
  • [2] Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US.
    Razavi, Pedram
    Ahmed, Mehnaj
    Roush, Ashley
    Parikh, Rohan
    Hitchens, Abigail
    Shen, Sherry
    Safonov, Anton
    Jhaveri, Komal L.
    Robson, Mark E.
    Peacock, Nancy Walker
    Ma, Yanjun
    Santarsiero, Elizabeth Chertow
    Ganapathy, Vaidyanathan
    Shah, Rohan M.
    Amefule, Adaeze Q.
    Lteif, Agnes
    Blakely, L. Johnetta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Evaluation of recurrence rate in Canadian patients with stage II/III HR+/HER2-early breast cancer in the real-world setting
    Marques, Maud
    Gambaro, Karen
    Basik, Mark
    Saad, Fred
    Hassan, Saima Noor
    Boudreau, Dominique
    Vincent, Francois
    St-Hilaire, Eve
    Mackay, Helen
    Abdelsalam, Mahmoud
    Guillemette, Stephanie
    Leite, Ricardo
    Caron, Marc-Andre
    Patel, Chandni
    Batist, Gerald
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2-early breast cancer
    O'Shaughnessy, Joyce
    Tolaney, Sara M.
    Yardley, Denise A.
    Hart, Lowell
    Razavi, Pedram
    Fasching, Peter A.
    Janni, Wolfgang
    Schwartzberg, Lee
    Kim, Julia
    Akdere, Murat
    McDermott, Courtney
    Khakwani, Aamir
    Pathak, Purnima
    Graff, Stephanie L.
    BREAST, 2025, 81
  • [5] Risk of Recurrence by Nodal Status and High-Risk Features in Patients with HR+, HER2-, Early Breast Cancer: An Analysis of Real-world Data
    Grimes, B.
    Tolaney, S. M.
    Sammons, S.
    Cortes, J.
    Liepa, A. M.
    Sugihara, T.
    Cui, Z. Lin
    Gathirua-Mwangi, W.
    Shahir, A.
    Monaco, M.
    Neven, P.
    Johnston, S.
    BREAST, 2025, 80
  • [6] Neoadjuvant and adjuvant therapy (NAT/AT) treatment patterns and clinical characteristics in a real-world cohort of US patients with HR+/HER2-early breast cancer (eBC)
    Downer, Mary K.
    Craggs, Christopher
    Dhillon, Preet
    Luhn, Patricia
    Flores-Avile, Carlos
    Tan, Amie
    Patre, Monika
    Schimmoller, Frauke
    Crnjevic, Tanja Badovinac
    CANCER RESEARCH, 2021, 81 (04)
  • [7] Clinical outcomes in patients (pts) with HR+/HER2-early breast cancer (EBC) by prior systemic treatment (tx): A subgroup analysis of the NATALEE trial
    McAndrew, N. P.
    Chia, S.
    Puglisi, F.
    Bardia, A.
    Izarzugaza Peron, Y.
    Schem, C.
    Xu, B.
    Le Du, F.
    Sharma, P.
    Afenjar, K.
    Akdere, M.
    Gonzalez, J. P. Zarate
    Chattar, Y.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2024, 35 : S315 - S316
  • [8] Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2-early breast cancer (EBC) from US electronic health records (EHR)
    Jhaveri, K.
    Pegram, M.
    Neven, P.
    Curigliano, G.
    Spring, L. M.
    Gligorov, J.
    Schlam, I.
    Harbeck, N.
    Juric, D.
    Lim, E.
    Wang, S.
    Owusu, H.
    Akdere, M.
    Ye, F.
    Kim, J.
    Cardoso, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S337 - S338
  • [9] The prediction of Oncotype DX risk group using clinicopathologic factors in patients with HR+/HER2-early breast cancer
    Song, R.
    Lee, D. -E.
    Lee, S.
    Kang, H. -S.
    Han, J. H.
    Lee, K. S.
    Sim, S. H.
    Chae, H.
    Kwon, Y.
    Woo, J.
    Lee, M.
    Lee, E. -G.
    Jung, S. -Y.
    BREAST, 2023, 68 : S74 - S75
  • [10] Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2-early breast cancer
    Graff, Stephanie L.
    Tolaney, Sara M.
    Hart, Lowell L.
    Razavi, Pedram
    Janni, Wolfgang
    Schwartzberg, Lee S.
    Danyliv, Andriy
    Akdere, Murat
    Ferrusi, Ilia
    Adhikary, Rishi Rajat
    O'Shaughnessy, Joyce A.
    CANCER, 2025, 131 (07)
1234